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Abstract
Background: PBX1 is a biological candidate gene for type 2 diabetes at the 1q21-q24 susceptibility
locus. The aim of this study was to evaluate the association of common PBX1 variants with type 2
diabetes in French Caucasian subjects.
Methods: Employing a case-control design, we genotyped 39 SNPs spanning the PBX1 locus in
3,093 subjects to test for association with type 2 diabetes.
Results: Several PBX1 SNPs, including the G21S coding SNP rs2275558, were nominally associated
with type 2 diabetes but the strongest result was obtained with the intron 2 SNP rs2792248 (P =
0.004, OR 1.20 [95% CI 1.06–1.37]). The SNPSpD multiple testing correction method gave a
significance threshold of P = 0.002 for the 39 SNPs genotyped, indicating that the rs2792248
association did not survive multiple testing adjustment. SNP rs2792248 did not show evidence of
association with the French 1q linkage signal (P = 0.31; weighted NPL score 2.16). None of the
PBX1 SNPs nominally associated with type 2 diabetes were associated with a range of quantitative
metabolic traits in the normoglycemic control subjects
Conclusion: The available data does not support a major influence of common PBX1 variants on
type 2 diabetes susceptibility or quantitative metabolic traits. In order to make progress in
identifying the elusive susceptibility variants in the 1q region it will be necessary to carry out further
large association studies, meta-analyses of existing data from individual studies, and deep
resequencing of the 1q region.
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Background
PBX1 is a strong biological candidate gene at the chromo-
some 1q21-q24 susceptibility locus [1]. It is a member of
the TALE (three amino acid loop) class of homeodomain
factors which regulate developmental gene expression in
heteromeric complexes with other transcription factors
[2]. Pbx1 null mice exhibit severe defects in pancreatic
exocrine and endocrine cell differentiation and die at E15-
16, while Pbx1+/- mice have pancreatic islet malformation,
impaired glucose tolerance and hypoinsulinemia [3]. In
vitro studies showed that Pbx1 binds cooperatively with
Pdx1 to the regulatory elements of target pancreatic genes,
such as somatostatin and elastase [4-6]. Pdx1-/-  mice
expressing a Pbx1-interaction defective transgene contain
all the various pancreatic cell types, but have markedly
smaller pancreata and islets than Pdx1-/- mice expressing
the wild-type Pdx1 transgene [7]. This suggested that
Pbx1:Pdx1 complexes are essential for normal prolifera-
tion after pancreatic cell type differentiation. In addition,
compound heterozygote Pbx1+/- Pdx1+/- mice exhibit an
age-dependent diabetes phenotype [7]. These findings
demonstrated that, at least in mice, Pbx1 plays a key role
in pancreatic development and that Pbx1 is an important
cofactor of Pdx1, a 'master regulator' of pancreatic devel-
opment and function [8]. Wang et al. [9] reported the
results of a small case-control study (192 diabetic cases
and 192 normoglycemic controls) in which 20 PBX1 var-
iants were evaluated for association with type 2 diabetes
in Utah Caucasians. Three variants were nominally associ-
ated (P < 0.05) with type 2 diabetes, as were haplotypes
involving intron 2 variants. In the present study, we set
out to perform a large association study of common PBX1
variation and type 2 diabetes in French Caucasians.
Methods
Case-control subjects
All subjects were of French Caucasian ancestry. Individu-
als identified by Sladek et al. [10] to lie outside the Hap-
Map CEU ancestry cluster were excluded from the study.
Type 2 diabetic case subjects were known diabetic
patients. Normoglycemic control subjects were selected to
have a fasting blood glucose concentration < 6.1 mM [11].
Case subjects were composed of: (i) 372 probands from
diabetic families, recruited in Lille; and (ii) 1083 patients
with a family history of T2D recruited at the Corbeil-
Essonne Hospital. Control subjects were composed of: (i)
372 normoglycemic parents from T2D families; (ii) 524
subjects from the SUVIMAX prospective population-
based cohort study [12]; and (iii) 742 subjects selected
from the DESIR cohort, a large prospective study of insu-
lin resistance in French subjects [13]. In total, the case-
control cohort comprised 1,455 type 2 diabetic subjects
(age, 60 ± 12 years; BMI, 29.0 ± 6.0 kg/m2; male/female,
56:44%) and 1,638 normoglycemic subjects (age, 54 ± 13
years; BMI, 24.1 ± 3.3 kg/m2; male/female, 43:57%). At α
= 0.05, this sample size provides 94% power to detect a
susceptibility allele with a frequency of 0.25, assuming a
disease prevalence of 0.1 and a heterozygote relative risk
of 1.2 (multiplicative model) [14]. Informed consent was
obtained from all subjects and the study was approved by
the local ethics committees.
PBX1 resequencing
The genomic target sequences for PBX1 resequencing con-
sisted of each of the 9 exons (NCBI RefSeq NM_002585)
together with ~500 bp flanking intronic sequence, 500 bp
of the 3' UTR and 1 kb of the 5' UTR. We sequenced these
regions in 24 unrelated probands taken from families
with the strongest evidence of linkage at 1q (NPL score ≥
0.816) [15]. PCR reactions (primer sequences are availa-
ble on request) were performed with 100 ng human
genomic DNA and AmpliTaq Gold polymerase (Applied
Biosystems, USA) using standard PCR conditions in a
total volume of 25 μl. Bi-directional sequencing reactions
were performed with the BigDye Terminator v.3.1 cycle
sequencing kit (Applied Biosystems, USA) and electro-
phoresed on the Applied Biosystems 3700 Genetic Ana-
lyzer according to the manufacturer's instructions.
Sequence alignment and analysis were carried out with
the Phred/Phrap/Consed system [16,17].
PBX1 SNP identification and selection
This study was initiated well before completion of the
HapMap project [18], and we employed a combination
SNP selection strategy involving: i) resequencing; ii) the
identification of preliminary association signals (P <
0.05) in the French case-control samples (n = 600) of the
International Type 2 Diabetes 1q Consortium dataset; and
iii) the extraction of SNPs from dbSNP. Resequencing
identified four common (MAF ≥ 5%) SNPs. The 1q Con-
sortium data highlighted six interim association signals at
the PBX1 locus, including the G21S variant and SNPs in
the 5' upstream region and the large 2nd intron (229 kb).
To provide additional genomic and functional coverage in
these regions, we identified common validated SNPs in:
~35 kb of the 5' upstream region at a density of 1.5 SNPs/
kb; and conserved noncoding regions (CNRs) in introns 1
and 2. CNRs were defined as ≥ 80% human-mouse iden-
tity across a 100 bp window in the VISTA database [19]. In
total, 39 SNPs at the PBX1 locus were tested for associa-
tion with type 2 diabetes.
SNP genotyping
Genotyping was performed with the Sequenom MassAR-
RAY system [20]. SNP genotype frequencies were tested
for accordance with Hardy-Weinberg equilibrium using
chi-squared analysis. Quality control criteria: SNPs with a
call rate < 90%, a MAF < 5%, a Hardy-Weinberg P < 0.05,
or that exhibited poorly defined genotype clusters were
disqualified from association analysis.BMC Medical Genetics 2008, 9:14 http://www.biomedcentral.com/1471-2350/9/14
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Statistical analyses
To test the association of PBX1 SNPs with type 2 diabetes,
chi-squared analysis of allelic and genotype counts was
performed. To address the multiple testing problem, the
SNPSpD method [21] was employed. Pairwise SNP LD
values were calculated and plotted with Haploview [22].
Quantitative metabolic phenotypes measured in the
1,638 normoglycemic subjects that comprised the control
cohort were log transformed and adjusted for age, sex and
BMI, as appropriate. SNPs were tested for association with
adjusted quantitative traits using SPSS 14.0 with the
ANOVA test under a codominant model. The program
GIST [23] was used to assess the contribution of SNPs to
the 1q linkage signal previously obtained with the 56
"strict lean" French families [15]. Meta-analysis was per-
formed with the Mantel-Haenszel [24] method estimating
the common odds ratio for combined allele counts using
SPSS 14; results are reported for the two-sided, asymptot-
ically distributed test.
Results
The  PBX1  gene locus extends for 287 kb
(162,795,561..163,082,934 bp NCBI36) on chromosome
1q23 and consists of 9 exons. We tested 39 SNPs spanning
the PBX1 locus for association with type 2 diabetes in
3,093 French subjects. Genotype call rates exceeded 90%
overall. The overlap between samples in the present study
and that of the 1q Consortium allowed us to determine
the genotype concordance rates for the six SNPs geno-
typed in common between the two datasets. Concordance
rates were all greater than 98% (Table S1, Additional file
1). The allelic and genotype count data for all genotyped
SNPs is presented in Tables S2 and S3, respectively (addi-
tional file 1). Several PBX1 SNPs, including the G21S var-
iant, were modestly associated with type 2 diabetes (Table
1), but the strongest result was obtained with the intron 2
SNP rs2792248 (P = 0.004, OR 1.21 [95% CI 1.06–1.39]),
which had shown preliminary association with type 2 dia-
betes in the 1q Consortium dataset. However, the
SNPSpD multiple testing correction method [21] gave a
significance threshold of P = 0.002 for the 39 SNPs geno-
typed (equivalent to 21 independent tests), indicating
that the rs2792248 result did not survive multiple testing
adjustment. There were no significant differences in SNP
allele frequencies between males and females (data not
shown).
There was weak LD between the genotyped SNPs (Fig. 1)
and thus we did not carry out haplotype analysis. In par-
ticular, SNP rs2792248 was not in LD with any other gen-
otyped markers. SNP rs2792248 did not show evidence of
contributing to the French 1q linkage signal (P = 0.31;
weighted NPL score 2.16). Interestingly, we did obtain
suggestive evidence under the additive model (P = 0.03;
weighted NPL score 3.87) that the minor allele of the
G21S variant was associated with the 1q linkage signal.
Finally, none of the PBX1 SNPs nominally associated with
type 2 diabetes were associated with a range of metabolic
quantitative traits in the normoglycemic control subjects
(Table S4, Additional file 1).
The availability of data from type 2 diabetes genome-wide
association studies (GWASs) prompted us to carry out a
meta-analysis of PBX1  variants genotyped in common
between the present study and the GWASs. However, only
three SNPs analysed here were successfully typed in the
two GWASs that published summary statistics (the DGI
[25] and WTCCC [26] studies). The nominally significant
associations of the upstream variants rs1338625 and
rs6426870 were not supported by the combined analysis
(P = 0.62, OR 0.98 [95% CI 0.92–1.05]; P = 0.82, OR 0.99
[95% CI 0.93–1.06], respectively); while the negative
result for rs4657364 was confirmed (P = 0.45, OR 1.03
[95% CI 0.95–1.12]) (Tables S5-7, Additional file 1).
Table 1: PBX1 SNPs nominally associated with type 2 diabetes in French Caucasians.
SNP Alleleb Chr Position 
(NCBI36)
Gene Region n subjects Allele 1 (%) Allele 2 (%) P OR (95% CI)
rs10918027 A/G 162765790 5' upstream T2D 1414 2128 (75) 700 (25) 0.040 1.14 (1.01–1.28)
NG 1567 2429 (78) 705 (22)
rs1338625 A/C 162780889 5' upstream T2D 1420 2107 (74) 733 (26) 0.039 1.13 (1.01–1.27)
NG 1576 2411 (76) 741 (24)
rs6662567 C/T 162783473 5' upstream T2D 1433 2140 (75) 726 (25) 0.040 1.13 (1.01–1.27)
NG 1574 2422 (77) 726 (23)
rs6426870 T/C 162790577 5' upstream T2D 1396 2073 (74) 719 (26) 0.014 1.16 (1.03–1.31)
NG 1542 2375 (77) 709 (23)
rs2275558 (G21S) a G/A 162795744 Exon 1 T2D 1427 2193 (77) 661 (23) 0.013 1.17 (1.03–1.32)
NG 1626 2584 (79) 668 (21)
rs2792248 a A/G 162891886 Intron 2 T2D 1178 1814 (77) 542 (23) 0.004 1.21 (1.06–1.39)
NG 1442 2121 (74) 763 (26)
a SNPs that showed evidence of association with T2D (P < 0.05) in the French samples of the 1q Consortium; b SNP alleles are shown as major/
minor.BMC Medical Genetics 2008, 9:14 http://www.biomedcentral.com/1471-2350/9/14
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Discussion
We have examined a number of common SNPs spanning
the PBX1 locus for association with type 2 diabetes in the
French population and obtained several nominal associa-
tion signals, of which the strongest was the intron 2 SNP
rs2792248. Despite the finding that this association disap-
peared upon correction for multiple testing, this finding
substantiated an association previously observed in the
small French sample set (n = 600) available to the 1q Con-
sortium. For this reason, it is possible that this is a bona
fide, albeit minor, association signal that was over-
whelmed by the sheer number of SNPs tested. Neverthe-
less, it appears unlikely from the data presented here (and
elsewhere – see below) that common PBX1 variants have a
major influence on susceptibility to type 2 diabetes. Before
formally rejecting PBX1 as a type 2 diabetes susceptibility
gene, however, we should make the point that PBX1 is a
large gene and the current study does not provide compre-
hensive coverage of common variation at the PBX1 locus.
According to HapMap data release #22, a total of 112 Hap-
Map II tag SNPs are required to capture the common vari-
ation across the region covered in this study at r2 ≥ 0.8 and
MAF ≥ 0.05. A comparison of this list with the SNPs geno-
typed in this study indicates that we typed a mere 18 tag
SNPs (or proxies) plus 11 other SNPs, equating to ~25% of
the common variation at PBX1. Thus, we are not able to
rule out the possibility that type 2 diabetes susceptibility
variants exist at the PBX1 locus. Nevertheless, our results
Pattern of linkage disequilibrium across the PBX1 locus Figure 1
Pattern of linkage disequilibrium across the PBX1 locus. Haploview plots of pairwise SNP LD values (r2) calculated 
from the pooled case-control genotype data.BMC Medical Genetics 2008, 9:14 http://www.biomedcentral.com/1471-2350/9/14
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are in general agreement with the type 2 diabetes GWASs,
none of which found strong association signals at PBX1 or
indeed anywhere within the 1q region [10,25-27].
The problem of identifying the genetic variants responsible
for the 1q linkage signal(s) has proven to be refractory to
progress, despite dense (1 SNP per 5 kb) region-wide gen-
otyping by the International 1q Consortium, a number of
individual candidate gene studies, as well as the genom-
ewide association scans. This preponderance of negative
results suggests that the various 1q linkages were generated
by a combination of many different common and/or rare
variants of small effect (OR 1.01–1.1) which reasonably
large studies (i.e. samples numbering in the thousands)
have only limited power to detect. If this is true, the way
forward at 1q will be to identify the common, minor sus-
ceptibility variants with meta-analyses of genotype data
from large individual studies; and to probe the contribu-
tion of rare variants by deep resequencing of the 1q region.
Conclusion
The available data do not support a major influence of
common PBX1 variants on type 2 diabetes susceptibility
or quantitative metabolic traits. In order to make progress
in identifying the elusive susceptibility variants in the 1q
region it will be necessary to carry out further large associ-
ation studies, meta-analyses of existing data from individ-
ual studies, and deep resequencing of the 1q region.
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